Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioMarin Pharmaceutical Inc. (BMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed rare disease biotechnology company, BioMarin files periodic and current reports that describe its financial condition, results of operations, governance changes and material corporate events.
Investors researching BMRN can review Forms 10-K and 10-Q for detailed discussions of BioMarin’s business, risk factors, rare disease portfolio and pipeline strategy. Current reports on Form 8-K, such as those announcing quarterly results, acquisitions, leadership changes or guidance updates, give insight into significant developments affecting the company’s Enzyme Therapies, Skeletal Conditions and gene therapy franchises.
Through this page, users can also track information that may appear in proxy materials and other filings, including board composition and committee appointments, executive roles and the company’s use of non-GAAP financial measures like Non-GAAP Operating Margin and Non-GAAP Diluted EPS, as described in its disclosures. For those monitoring corporate actions, merger agreements, or business development transactions, the related 8-K filings and exhibits are a primary source of official information.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping readers interpret long or technical documents. Real-time updates from EDGAR, combined with structured access to forms such as 10-K, 10-Q and 8-K, allow investors to follow BioMarin’s regulatory reporting history and understand how management communicates strategy, performance and risk to the market.
BioMarin Pharmaceutical CEO Alexander Hardy reported new equity awards and a routine tax withholding. On March 16, 2026, he received a grant of 89,200 stock options to buy common stock at an exercise price of $57.43 per share, expiring on March 15, 2036. The option grant vests 12/48 on March 16, 2027 and 1/48 on the 16th day of each month thereafter. He was also granted 62,440 restricted stock units on the same date, with price not applicable. On March 13, 2026, 2,941 shares of common stock were withheld at $58.51 per share to cover tax obligations. Following these transactions, Hardy directly owned 218,887 shares of BioMarin common stock.
BioMarin Pharmaceutical Inc. is halting dosing and enrollment in its Phase 2 trials of VOXZOGO for Turner syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency. This decision follows several slipped capital femoral epiphysis (SCFE) events reported in two ongoing investigator-sponsored trials using VOXZOGO in these conditions.
BioMarin states that SCFE has not been seen in its own Phase 2 trials in these indications, nor among more than 5,000 infants and children treated with VOXZOGO for achondroplasia over about 10,000 patient-years of clinical and post-marketing safety data. No SCFE cases have appeared in VOXZOGO trials for hypochondroplasia. The Phase 2 CANOPY trials of VOXZOGO will continue for children with Noonan syndrome and for most participants with idiopathic short stature without ACAN-deficiency.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer sold common shares in an open-market transaction. On March 11, 2026, he sold 16,486 shares of BioMarin common stock at a weighted average price of $60.46 per share, with individual sale prices ranging from $60.39 to $60.62. After this sale, he directly held 79,953 shares of BioMarin common stock.
BMRN Form 144 filing reporting an intended sale of Common Stock through a broker. The filing lists Fidelity Brokerage Services LLC as the broker and shows 03/11/2026 as a filing date.
The filing itemizes securities tied to compensation and ESPP with quantities and dates: 1,857 shares (restricted stock vesting on 05/04/2023), 133 shares (ESPP purchase on 10/31/2023), and 14,496 shares (restricted stock vesting on 03/15/2024).
Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical executive Charles Greg Guyer, EVP and Chief Technical Officer, reported three equity awards credited on February 25, 2026. The awards represent performance-based restricted stock units earned for results over 2023–2025 tied to relative total shareholder return, development goals, and core operating margin, vesting on March 15, 2026 if he remains in service.
BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026. The shares were sold at a weighted average price of $60.3758 per share, with individual sale prices ranging from $60.36 to $60.51 according to the footnote. After this transaction, Friberg directly holds 37,578 shares of BioMarin common stock.
BioMarin Pharmaceutical EVP and Chief Legal Officer George Eric Davis reported both stock sales and equity awards. On February 26, 2026, he completed an open-market sale of 26,061 shares of common stock at $61.36 per share, leaving 72,453 shares held directly afterward.
On February 25, 2026, he acquired three blocks of common stock through grants or awards totaling 15,224 earned restricted stock units (RSUs), all at a stated price of $0.00 per share. These RSUs were earned under performance-based awards tied to relative total shareholder return, development goals, and core operating margin for 2023–2025, and will vest on March 15, 2026 subject to continued service and certain earlier-vesting events.
BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards. On February 25, 2026, he acquired 6,683, 7,230, and 2,569 shares of common stock at $0 per share through grants classified as awards, not open-market purchases.
These shares come from Restricted Stock Units earned for performance over 2023–2025, based on relative total shareholder return, development goals, and core operating margin. The earned RSUs convert into common stock on a 1:1 basis and are scheduled to vest on March 15, 2026, subject to his continued service, with earlier vesting possible upon certain events. Following these awards, he directly owns 116,638 common shares.
BioMarin Pharmaceutical Inc. notice of proposed sale of common stock on a Form 144 through a broker-dealer. The filing lists Fidelity Brokerage Services LLC and references proposed transactions tied to restricted stock vesting on 09/30/2025 (5928 shares) and an ESPP purchase on 10/31/2025 (398 shares). The form records the broker and an entry date of 02/26/2026.
BioMarin Pharmaceutical reports 2025 total revenues of $3.2 billion, driven largely by growth in VOXZOGO and its enzyme therapy franchise. VOXZOGO generated $926.9 million in 2025 net product revenue, while enzyme therapies and other rare-disease drugs added diversified sales.
The company agreed in December 2025 to acquire Amicus Therapeutics for $4.8 billion in cash, funded by cash on hand, $850.0 million of 5.5% senior notes due 2034, and an expected $2.8 billion term loan plus a $600.0 million revolving credit facility. BioMarin plans to expand its portfolio with Fabry and late‑onset Pompe disease therapies.
BioMarin is exiting ROCTAVIAN after lower‑than‑anticipated commercial opportunities, recording about $240.0 million in 2025 restructuring charges for inventory write‑offs, asset impairments, and severance. As of February 19, 2026, it had 192,323,359 shares of common stock outstanding and continues advancing a robust pipeline, including BMN 333, BMN 351, and BMN 401.